FALSE000089626400008962642026-05-202026-05-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 20, 2026
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Utah
(State or other jurisdiction of incorporation)
001-3502487-0500306
(Commission File No.)(IRS Employer
Identification No.)
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareUSNANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07     Submission of Matters to a Vote of Security Holders.        

The Company held its Annual Meeting of Shareholders on May 20, 2026. A total of 16,468,210 shares (approximately 89%) of the issued and outstanding shares of USANA common stock were represented by proxy or in person at the meeting. The following matters were submitted and voted upon at the Annual Meeting:

1.USANA shareholders voted to elect eight individuals to the Board of Directors for the succeeding year as set forth below:

NameNumber of Shares ForNumber of Shares WithheldNumber of Shares AbstainingBroker Non-Votes
Kevin G. Guest 14,134,096201,166-2,132,948
Xia Ding 14,098,411236,851-2,132,948
John T. Fleming 14,098,006237,256-2,132,948
Gilbert A. Fuller 13,687,065648,197-2,132,948
J. Scott Nixon, CPA14,095,270239,9922,132,948
Peggie J. Pelosi 14,023,243312,019-2,132,948
Frederic Winssinger 14,093,666241,596-2,132,948
Timothy E. Wood, Ph.D. 14,097,463237,799-2,132,948


2.USANA shareholders voted to ratify the Board’s selection of KPMG LLP as our independent registered public accounting firm for fiscal year 2026 as set forth below:

Number of Shares ForNumber of Shares AgainstNumber of Shares AbstainingBroker Non-Votes
16,286,742151,73629,732-


3.USANA shareholders voted to approve, on an advisory basis, executive compensation as set forth below:

Number of Shares ForNumber of Shares AgainstNumber of Shares AbstainingBroker Non-Votes
13,811,489509,77713,9962,132,948


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
USANA HEALTH SCIENCES, INC.
By:/s/ G. Douglas Hekking
G. Douglas Hekking, Chief Financial Officer
Date: May 20, 2026